OPIOID OVERDOSE PREVENTION Guidance for Implementing Overdose Prevention in Schools Presented by Debra Carey, MS, PPCNP-BC, AE-C November 2016
Background • Deaths from opioid overdoses have reached epidemic levels in our community over the past 2 years According to ECDOH statistics, 44.5% of those deaths occurred in the suburbs • What precipitated this unprecedented increase in opioid overdoses? NYS institutes I-STOP prescription monitoring system, causing increased use of street drugs
To combat the continuing rise in opioid–related deaths in NYS, laws were recently enacted allowing schools to provide and maintain opioid- antagonists (naloxone) on-site in each facility to ensure ready and appropriate access for use during emergencies to any student or staff suspected of having opioid overdose
Statutory Framework for Opioid Overdose Prevention in NYS • Public Health Law§3309 and its implementing regulations in 10 NYCRR §80.138 establish the framework for regulated community access to naloxone. • The law states use of an opioid antagonist pursuant to this section shall be considered first aid or emergency treatment for the purpose of any statute relating to liability. • This law allows trained non-medical, unlicensed persons to use naloxone on individuals suspected of an opioid overdose if trained by a NYSDOH approved training curriculum.
Chapter 57 of the Laws of 2015 added Education Law §922 • Permits NYS school districts, BOCES, charter schools, non-public elementary and/or secondary schools to provide and maintain opioid antagonists on site in each instructional facility to ensure emergency access for any student or school personnel having opioid overdose symptoms, whether or not they have a previous known history of opioid abuse. • Any person employed by any such entity that has elected to participate may administer an opioid antagonist in the event of an emergency, provided that such person shall have been trained by a program approved under section three thousand three hundred nine of the public health law.
"Good Samaritan Law" Public Health Law, Article 30-Section 3000-a • Covers the liability of the non-licensed person when responding to an emergency situation • any person who voluntarily …renders first aid or emergency treatment …to a person who is unconscious, ill, or injured, shall not be liable for damages for injuries alleged to have been sustained by such person or for damages for the death of such person ..” • Naloxone is a “do no harm drug” because it only affects persons with opiates in their system
Naloxone (Narcan) is an opioid reversal agent
Options The district may opt not to maintain naloxone on-site for emergency first-aid, and EMS will be responsible for provision of care, OR The district may elect to participate in the opioid overdose prevention program and choose the most appropriate option for participation.
OPTION #1- Becoming a NYSDOH Registered Opioid Overdose Prevention Program Create district approved procedures. • Designate a program director, in the school district may be the • Superintendent, Principal, RN or district designee, with overall responsibility for the program Designate a clinical director, in the school district this must be the medical • director, who is a duly licensed physician or nurse practitioner, to provide clinical oversight of the program. Refer to the New York Statewide School Health Services (NYSSHSC) • website to review instructions for submitting the NYSDOH Registration Form to become a NYSDOH Registered Opioid Overdose Program.
OPTION #1- Becoming a NYSDOH Registered Opioid Overdose Prevention Program, continued Train volunteer, unlicensed school staff as overdose responders • using the NYSDOH approved training webinar located on the NYSSHSC website. Unlicensed school staff can only participate if the school district registers with the NYSDOH. Obtain naloxone. School districts registered as NYSDOH opioid • overdose programs will receive free naloxone kits which will be sent directly to the clinical director (medical director). Establish and maintain a record keeping system for both responder • training and naloxone inventory. Notify administrations of opioid antagonists to the clinical and • program director so that they may report to the NYSDOH.
Clinical Director (School District Medical Director) Responsibilities Obtain naloxone as the designated prescriber for administration by volunteer • trained unlicensed school personnel and/or RN’s. Create protocols for responding to suspected opioid overdoses. • The training program has already been developed in conjunction with the • NYSDOH, and has received approval and endorsement by the NYSDOH to implement a school opioid overdose prevention program. Additional, guidance has been developed to ensure all responders are properly trained, which in school district could be a licensed medical professional such as the RN that can verify training and complete a compliance checklist. Designate medical professionals in the school district (RNs), to furnish or provide • shared access of naloxone to volunteer trained unlicensed responders. Shared access of naloxone located in a central location is permitted as long as responders are trained in accordance with the NYSDOH regulations, have a common organizational or workforce bond such as being part of the same school/school district, and there are policies and procedures in place within that organization to ensure orderly, controlled access to an opioid antagonist by an identifiable pool of trained overdose responders. Review reports of all administrations of naloxone and report to program director • and NYSDOH.
OPTION #2- Issuing a Non-Patient Specific Order • As a NYS licensed prescriber, the school’s medical director can issue a non-patient specific order to school nurses (RNs) to administer naloxone. • Under this option the medical director, in collaboration with school administration will acquire the naloxone and provide to the school. • School districts who choose to utilize this method of implementing an opioid overdose prevention program are not eligible to receive naloxone from NYSDOH.
Option #3:Permitting Volunteers to be trained by a NYSDOH Registered Overdose Prevention Program Schools without medical directors may permit volunteer unlicensed • school personnel to be trained to administer IN naloxone by collaborating with a NYSDOH Registered Overdose Prevention Program in their area. The school will become a participant under an already established • registered program, and will be provided a NYSDOH approved training curriculum and receive free IN naloxone kits. Prior to contacting a NYSDOH Registered Program, schools must • have approval from their governing body, and have approved policies and procedures in place. Schools that do not have a medical director but are electing to participate must have policies and procedures approved by the BOE or governing body in place prior to contacting a NYSDOH Registered Program in their area. These schools will then need to link with a New York State DOH-registered opioid overdose prevention program for purposes of training non- licensed personnel and furnishing them with naloxone.
What are other school districts doing? Numerous local districts have registered as Opioid Overdose Prevention Programs. (Amherst, Erie 1 BOCES, Hamburg, Lockport, Williamsville [ in process] ) Some have chosen to use non-patient specific orders. (Clarence, Sweet Home, Frontier) Some districts have chosen not to maintain naloxone on-site, and intend to rely on EMS response. (Niagara Falls)
Recommendation for Ken Ton UFSD To ensure the health & safety of our students & staff, an Opioid Overdose Prevention policy should be incorporated as emergency care and first aid for a life-threatening condition. It is the opinion of the district nurse practitioner medical director that the most effective policy choice is Option #1: Become a New York State registered opioid overdose prevention program
Rationale • School should be responsible for anticipating and preparing to respond to a variety of emergencies • When administered quickly and effectively, naloxone has the potential to immediately restore breathing to a victim experiencing an opioid overdose
Conclusion Opioid overdose is a crisis in our community, and overdose prevention saves lives. Naloxone is considered first aid or emergency treatment, and should be available in our schools for students and staff. It is inexpensive, safe, & effective.
Resources Additional information is available at the NYSDOH Opioid Prevention webpage: http://www.health.ny.gov/overdose & New York Statewide School Health Services Center link: http://www.schoolhealthservicesny.com
CRF01_AE: Do we need a customized CCR5 antagonist treatment recommendation? Nico Pfeifer Max Planck Insitute for Informatics HIV coreceptor usage HIV coreceptor usage HIV coreceptor usage HIV coreceptor usage CRF01_AE update Recent
367 views • 15 slides
Calculation of the Minimum Anticipated Biological Effect Level (MABEL) and 1 st dose in human Jennifer Sims, PhD AstraZeneca Member of ABPI / BIA Early Stage Clinical Trials Taskforce Slide 1 Acknowledgements Acknowledgements ABPI/ BIA
482 views • 25 slides
Independent Novel Project: Google Slides Document Criteria Students will read a novel independently and create a fifteen-slide Google Slides document according to the slide outline below. They should include bulleted points, at least eighteen-
415 views • 3 slides
Apixaban vs VKA and Aspirin vs Placebo in Patients with Atrial Fibrillation and ACS/PCI: The AUGUSTUS Trial Renato D. Lopes, MD, PhD on behalf of the AUGUSTUS Investigators Background The optimal antithrombotic regimen for patients with
462 views • 23 slides
The Glucagon Receptor Antagonist LGD-6972 Reduces Fasting and Postprandial Glucose in a Multiple-Dose Clinical Trial Eric G Vajda 1 , Douglas Logan 2 , Kenneth Lasseter 3 , Danielle Armas 4 , Diane J. Plotkin 5 , J.D. Pipkin 1 , Yong-Xi Li 2 ,
414 views • 15 slides
DISCLOSURE No disclosures, financial, or otherwise to declare ANATOMY CARDIOPULMONARY BYPASS CABG VALVE SURGERY Which valve? - Aortic, Mitral, Tricuspid Repair vs Replacement Replacement Mechanical vs Bioprosthetic i.e.
986 views • 65 slides
5/4/2016 Disclosure Information PT2385: HIF 2 Antagonist for the Treatment of Eli Wallace VHL Mutant ccRCC I have the following financial relationships to disclose: I am a stockholder and employee of Peloton Therapeutics, Inc. 12th
651 views • 5 slides
The Presentation Genius of Steve Jobs Table of Contents Steve Jobs Presentation Genius .....................................................................................................................................................1
1.39k views • 12 slides
Affimer fimer Biother therapeut apeutics: ics: Th The precl eclinical inical develo velopment pment and valida lidation tion of a PD PD-L1 1 anta tagonist onist in mouse use th Jun NGP GPT San an Diego, go, 6 th une 2017 Amrik
616 views • 30 slides
Protein Kinase C- ( PKC- ) Inhibition: A Promise not yet Fulfilled Ruboxistaurin, an oral PKC- , was withdrawn on March 15, 2007 by Eli Lilly Dual Inhibition of Classical Protein Kinase C- and Protein Kinase C- Isoforms Protects
415 views • 13 slides
BLU-5937: A Highly Selective P2X3 Homotrimeric Receptor Antagonist, Exhibits Excellent Pharmacokinetic and Safety Profile Including Improved Taste Safety Profile in Healthy Subjects Denis Garceau 1 , Nathalie Chauret 1 and Laurent Harvey 1 1
235 views • 10 slides
A small molecule glycomime.c antagonist of E-selec.n and CXCR4 (GMI-1359) delays pancrea.c tumor metastasis and significantly alters the pancrea.c tumor
412 views • 20 slides
We are a responsibly - driven company focused on achieving the most efficient development of products that address significant unmet needs in CNS disorders and in rare diseases SEELOS THERAPEUTICS June 2019 FORWARD-LOOKING STATEMENTS
458 views • 27 slides
Case Presentation Case Presentation 79 year old gentleman underwent CABG 10 years ago: SVG to the LAD, SVG to the obtuse Coronary Artery Disease Coronary Artery Disease marginal branch, and SVG to the ramus intermedius vessel John A Larry
397 views • 14 slides
Intracoronary Compared with Intravenous Bolus Abciximab Application During Primary Percutaneous Coronary Intervention Cardiac Magnetic Resonance Substudy of the AIDA STEMI trial Holger Thiele, MD; Jochen Whrle, MD; Henning Suenkel, BSc;
453 views • 24 slides
Dr. Sudarshan subedi et al., IJSIT, 2018, 7(2), 205-210 CASE PRESENTATION OF ST SEGMENTS ELEVATION IN LEAD AVR: ELECTROCARDIOGRAPHIC AND ANGIOGRAPHIC FINDINGS Dr. Sudarshan subedi 1* and Prof. Dr. Yang Shaning 2 1 Department of Cardiology, The
237 views • 6 slides
Supraventricular tachycardia from a left bundle branch block-An unusual presentation of Wolff- Parkinson-White syndrome Author(s): Abdul Rahim Wong, Nabil AbdurRazak, Saad Mohammad, Al-Hadlaq, Aida Hanum Ghulam Rasool, Abdullah Al-Jarallah Vol.
400 views • 5 slides
Machine Learning Methods for Mortality Prediction in Patients with ST Elevation Myocardial Infarction J. Vomlel 1 , H. Kru k 2 , P. T uma 2 , J. P cek 3 , and M. Hutyra 3 z re 1 Institute of Information Theory and Automation (
1.1k views • 60 slides
Disclosures: Rapid 12-Lead EKG Interpretation Goals for todays ECG Review: email@example.com Determine Right vs Left bundle branch block Diagnose Acute MI Diagnose old MI Location of the infarct
495 views • 24 slides
ICD-10 Provider Education Antonietta Sculimbrene, MD MHA October 20 15 Avoid claims processing errors=denials or claim rejections for providers, by fostering an understanding of the process of and reasoning behind Palmettos development of
418 views • 26 slides
12/2/2014 NAMAS Cardiology Breakout Cathy Huyghe, CPC Objectives Discuss the importance of data quality in auditing Apply medical necessity guidelines to Evaluation and Management services Hear the 2015 Coding update for
706 views • 25 slides
HEART FAILURE Study day November 2018 Sarah Briggs Overview and Introduction This course is an introduction and overview of heart failure. Normal heart function and basic pathophysiology of heart failure is explained. This will be then
1.03k views • 66 slides
Downloaded from http://bmjopen.bmj.com/ on January 12, 2018 - Published by group.bmj.com Open Access Research Clinical value of chest pain presentation and prodromes on the assessment of cardiovascular disease: a cohort study John Robson, 1
252 views • 7 slides
Objectives Review the impact of stroke, recognize signs and symptoms ACUTE STROKE CARE FOR Define risk factors Learn Pathophysiology of stroke THE EMS PROVIDER Learn Pre-hospital recommendations for Dispatch and EMS and
621 views • 16 slides